AD/PD Highlights

Dr Sharon Cohen joins touchNEUROLOGY to discuss the challenges in diagnosing Alzheimer’s disease (AD) at an early stage, the most exciting recent developments in diagnostic criteria, genetic testing, and neuroimaging techniques. Dr Cohen also talks through the recent developments in biomarker strategies for diagnosis and precision management of early AD. The presentation entitled: ‘Accelerating Progress […]

Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses the key clinical highlights and hot topics in movement disorders and Parkinson’s disease. Questions: What are the key clinical highlights from the past year in the field of movement disorders and Parkinson’s disease? Disclosures: Prof. Angelo Antonini is a consultant for AbbVie, Bial, […]

Gastrointestinal dysfunctions represent one of the main non-motor symptoms in Parksinon’s disease (PD). Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses a study that investigated α-Synuclein seeding activity in stomach-duodenum biopsies of PD patients by real-time quaking induced conversion (RT-QuIC) assay. The results suggest a deeper investigation in detection of α-Synuclein […]

α-Synuclein conformations are discussed as potentially novel blood biomarkers in Parkinson’s disease (PD). Dr Tim Bartels (UK Dementia Research Institute, University College London, London, UK) joins touchNEUROLOGY to discuss an ultrasensitive assay with antibodies directed against α-Synuclein multimers in blood, which may help to detect slight and early changes in this possible novel PD biomarker. […]

Dr Tim Bartels (UK Dementia Research Institute, University College London, London, UK) joins touchNEUROLOGY to discuss the highlights from this year’s AD/PD 2022 conference. He discusses some of his personal highlights in the field of new therapeutics for neurodegeneration, and also the presentation of functioning MRI agents for α-Synuclein. Question: What are some of the […]

Sargramostim, an innate immune system modulator, has been FDA approved for treating leukopenia for many years. Sargramostim has been investigated in this phase 2 study to determine if it can safely halt or reduce cognitive decline and brain pathology in participants with mild-to-moderate Alzheimer’s disease. Prof. Huntington Potter (University of Colorado, Denver, MS, USA) joins […]

It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]

It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]

It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The 15th International Conference for Alzheimer’s […]